Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 1,574 of 2,218.
    «« First « Previous 1570  1571  1572  1573  1574  1575  1576  1577  1578  Next» Last»»
    EudraCT Number: 2018-002125-30 Sponsor Protocol Number: AELIX-003 Start Date*: 2019-05-09
    Sponsor Name:AELIX Therapeutics
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection
    Medical condition: Human immunodeficiency virus type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: View results
    EudraCT Number: 2014-002382-30 Sponsor Protocol Number: RDD677 Start Date*: 2015-03-13
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer:
    Medical condition: Resectable Biliary Tract Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017621 Gallbladder carcinoma localized LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034446 Periampullary carcinoma resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-000629-32 Sponsor Protocol Number: MO17092 Start Date*: 2006-12-21
    Sponsor Name:University of Oxford
    Full Title: Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
    Medical condition: adjuvant treatment of colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-000687-27 Sponsor Protocol Number: CLIC477D2303E01 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder
    Medical condition: Bipolar I disorder, manic and mixed episodes DSM-IV criteria 296.0, 296.4 or 296.6
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001621-16 Sponsor Protocol Number: 04516 Start Date*: 2007-08-26
    Sponsor Name:University College London (UCL)
    Full Title: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky fillicular lymphoma
    Medical condition: Advanced stage, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005546-39 Sponsor Protocol Number: 905-EC-003 Start Date*: 2006-12-11
    Sponsor Name:Astellas Pharma Europe BV
    Full Title: SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACT...
    Medical condition: Solifenacin succinate is indicated for the relief of symptoms of urinary frequency, nocturia and urgency with or without incontinence, associated with overactive bladder 10059617
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) HU (Completed) CZ (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-004710-16 Sponsor Protocol Number: TPU-S1301 Start Date*: 2005-07-01
    Sponsor Name:Taiho Pharma USA, Inc.
    Full Title: An open label, multicenter, randomized, phase 3 study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously un...
    Medical condition: Advanced gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) DE (Completed) EE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022235-10 Sponsor Protocol Number: ITCC-015/EWOG-MDS-Azacytidine-2010 Start Date*: 2012-03-07
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML
    Medical condition: Relapsed advanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054439 Juvenile chronic myelomonocytic leukemia LLT
    20.0 100000004864 10068361 MDS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001659-32 Sponsor Protocol Number: M14-360 Start Date*: 2016-10-05
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed ...
    Medical condition: Stage III Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003350-99 Sponsor Protocol Number: Ringerfundin-01/2005 Start Date*: 2005-08-26
    Sponsor Name:B. Braun Medical s.r.o.
    Full Title: METABOLIC EFFECT OF RINGERFUNCIN B. BRAUN IN HEALTHY VOLUNTEERS AND COMPARISON WITH IONIC SOLUTION PLASMA-LYTE BAXTER
    Medical condition: healthy voluntaries
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003828-21 Sponsor Protocol Number: 71617 Start Date*: 2020-02-10
    Sponsor Name:St Antonius Hospital
    Full Title: Identification of sentinel lymph nodes in breast cancer patients through non-invasively and percutaneously fluorescent imaging using indocyanine green
    Medical condition: Axillar staging in breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000513-12 Sponsor Protocol Number: NR 9284-3 Start Date*: 2007-02-15
    Sponsor Name:Úrazová nemocnice brno
    Full Title: Terlipressin in the treatment of catecholamine-resistant septic shock
    Medical condition: Septic shock refractory to standard dose of norepinephrine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004727-36 Sponsor Protocol Number: NR 8230-3/2004 Start Date*: 2005-02-10
    Sponsor Name:Charles University, 3rd Faculty of Medicine
    Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.
    Medical condition: Prolonged phase of critical illness after severe multiple trauma
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000789-35 Sponsor Protocol Number: HPTM06/J/05 Start Date*: 2006-10-06
    Sponsor Name:INFAI GmbH
    Full Title: Two-way Crossover Comparison of the Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal vs. Standard 13C-Urea Breath Test in Helicobacter Pylori Positive and Neg...
    Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) without interuption of medication two weeks prior to test.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002767-98 Sponsor Protocol Number: UCDCRC/19/01 Start Date*: 2020-05-28
    Sponsor Name:University College Dublin
    Full Title: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)
    Medical condition: Patients with Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001998-40 Sponsor Protocol Number: GO29833 Start Date*: 2016-03-01
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIM...
    Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001710-15 Sponsor Protocol Number: GINECO-BR110 Start Date*: 2013-07-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: Phase II study in patient in first line for HER - metastasis breast cancer treated with eribulin and bevacizumab
    Medical condition: Patient with breast adenocarcinoma
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2023-000584-31 Sponsor Protocol Number: 402-C-120 Start Date*: 2023-07-06
    Sponsor Name:Pacira Pharmaceuticals, Inc.
    Full Title: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Local Administration of EXPAREL for Postsurgical Analgesia in Pediatric Subjects 12 to Less Than 17 Years of Age
    Medical condition: postsurgical pain
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003666-20 Sponsor Protocol Number: P1606-SUR-O25 Start Date*: 2023-05-09
    Sponsor Name:Immunovaccine Technologies Inc. (IMV Inc.)
    Full Title: Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant, Epithelial Ovarian Cancer (AVALON)
    Medical condition: Platinum Resistant Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001432-22 Sponsor Protocol Number: IC2013-05 Start Date*: 2014-07-25
    Sponsor Name:INSTITUT CURIE
    Full Title: A Multicenter Open label Phase II study of Pomalidomide and Cyclophosphamide and Dexamethasone in relapse/refractory Multiple Myeloma patients who were first treated within the IFM/DFCI 2009 trial
    Medical condition: Progressive/Refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1570  1571  1572  1573  1574  1575  1576  1577  1578  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 06:18:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA